Limits...
Protamine nanoparticles for improving shRNA-mediated anti-cancer effects.

Liu M, Feng B, Shi Y, Su C, Song H, Cheng W, Zhao L - Nanoscale Res Lett (2015)

Bottom Line: Protamine nanoparticles were designed by encapsulating small hairpin RNA (shRNA)-expressing plasmid DNA targeting the Bcl-2 gene (shBcl-2) to silence apoptosis-related Bcl-2 protein for improving the transfection efficiency and cytotoxicity in cancer therapy.Our findings demonstrated that the obtained protamine nanoparticles possessed excellent characterizations of small particle size, homogenous distribution, positive charge, and high encapsulation efficiency of gene. shBcl-2 loaded in nanoparticles (NPs) was protected effectively from the degradation of DNase I and serum.More importantly, it significantly improved the efficiency of transfection of shRNA in vitro in A549 cells and increased its cytotoxicity and induced more cell apoptosis by silencing Bcl-2.

View Article: PubMed Central - PubMed

Affiliation: School of Pharmacy, Liaoning Medical University, Jinzhou, 121000 People's Republic of China.

ABSTRACT
Protamine nanoparticles were designed by encapsulating small hairpin RNA (shRNA)-expressing plasmid DNA targeting the Bcl-2 gene (shBcl-2) to silence apoptosis-related Bcl-2 protein for improving the transfection efficiency and cytotoxicity in cancer therapy. Our findings demonstrated that the obtained protamine nanoparticles possessed excellent characterizations of small particle size, homogenous distribution, positive charge, and high encapsulation efficiency of gene. shBcl-2 loaded in nanoparticles (NPs) was protected effectively from the degradation of DNase I and serum. More importantly, it significantly improved the efficiency of transfection of shRNA in vitro in A549 cells and increased its cytotoxicity and induced more cell apoptosis by silencing Bcl-2.

No MeSH data available.


Related in: MedlinePlus

Viability of A549 cells after treatment with free shBcl-2 and shBcl-2-loaded NPs. Viability of A549 cells after treatment with free shBcl-2 and shBcl-2-loaded NPs with the concentrations of shBcl-2 at 6, 10, and 15 ng/μL. *P < 0.05, vs the free shBcl-2 group treated with A549 cells.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4385308&req=5

Fig3: Viability of A549 cells after treatment with free shBcl-2 and shBcl-2-loaded NPs. Viability of A549 cells after treatment with free shBcl-2 and shBcl-2-loaded NPs with the concentrations of shBcl-2 at 6, 10, and 15 ng/μL. *P < 0.05, vs the free shBcl-2 group treated with A549 cells.

Mentions: The inhibiting effects of free shBcl-2 and shBcl-2-loaded NPs on the amplification of A549 cells were determined by MTT assay. It can be seen from Figure 3 that shBcl-2-loaded NPs showed higher cytotoxicity at different concentration than free shBcl-2, suggesting that more shBcl-2 in NPs were transported into cells with the mediation of internalization of NPs. It also indicated that different from penetration of free drug into cells, cellular uptake of shBcl-2-loaded NPs may depend on endocytosis and macropinocytosis and induced the sufficient internalization of NPs in cells. Therefore, cytotoxic effects of shBcl-2-loaded NPs were higher than those of free shBcl-2.Figure 3


Protamine nanoparticles for improving shRNA-mediated anti-cancer effects.

Liu M, Feng B, Shi Y, Su C, Song H, Cheng W, Zhao L - Nanoscale Res Lett (2015)

Viability of A549 cells after treatment with free shBcl-2 and shBcl-2-loaded NPs. Viability of A549 cells after treatment with free shBcl-2 and shBcl-2-loaded NPs with the concentrations of shBcl-2 at 6, 10, and 15 ng/μL. *P < 0.05, vs the free shBcl-2 group treated with A549 cells.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4385308&req=5

Fig3: Viability of A549 cells after treatment with free shBcl-2 and shBcl-2-loaded NPs. Viability of A549 cells after treatment with free shBcl-2 and shBcl-2-loaded NPs with the concentrations of shBcl-2 at 6, 10, and 15 ng/μL. *P < 0.05, vs the free shBcl-2 group treated with A549 cells.
Mentions: The inhibiting effects of free shBcl-2 and shBcl-2-loaded NPs on the amplification of A549 cells were determined by MTT assay. It can be seen from Figure 3 that shBcl-2-loaded NPs showed higher cytotoxicity at different concentration than free shBcl-2, suggesting that more shBcl-2 in NPs were transported into cells with the mediation of internalization of NPs. It also indicated that different from penetration of free drug into cells, cellular uptake of shBcl-2-loaded NPs may depend on endocytosis and macropinocytosis and induced the sufficient internalization of NPs in cells. Therefore, cytotoxic effects of shBcl-2-loaded NPs were higher than those of free shBcl-2.Figure 3

Bottom Line: Protamine nanoparticles were designed by encapsulating small hairpin RNA (shRNA)-expressing plasmid DNA targeting the Bcl-2 gene (shBcl-2) to silence apoptosis-related Bcl-2 protein for improving the transfection efficiency and cytotoxicity in cancer therapy.Our findings demonstrated that the obtained protamine nanoparticles possessed excellent characterizations of small particle size, homogenous distribution, positive charge, and high encapsulation efficiency of gene. shBcl-2 loaded in nanoparticles (NPs) was protected effectively from the degradation of DNase I and serum.More importantly, it significantly improved the efficiency of transfection of shRNA in vitro in A549 cells and increased its cytotoxicity and induced more cell apoptosis by silencing Bcl-2.

View Article: PubMed Central - PubMed

Affiliation: School of Pharmacy, Liaoning Medical University, Jinzhou, 121000 People's Republic of China.

ABSTRACT
Protamine nanoparticles were designed by encapsulating small hairpin RNA (shRNA)-expressing plasmid DNA targeting the Bcl-2 gene (shBcl-2) to silence apoptosis-related Bcl-2 protein for improving the transfection efficiency and cytotoxicity in cancer therapy. Our findings demonstrated that the obtained protamine nanoparticles possessed excellent characterizations of small particle size, homogenous distribution, positive charge, and high encapsulation efficiency of gene. shBcl-2 loaded in nanoparticles (NPs) was protected effectively from the degradation of DNase I and serum. More importantly, it significantly improved the efficiency of transfection of shRNA in vitro in A549 cells and increased its cytotoxicity and induced more cell apoptosis by silencing Bcl-2.

No MeSH data available.


Related in: MedlinePlus